Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer

靶向三阴性乳腺癌的主要免疫逃避途径

基本信息

  • 批准号:
    10224146
  • 负责人:
  • 金额:
    $ 48.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-01 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

Therapeutic Targeting of a Major Immune Resistance Pathway in Triple-negative Breast Cancer Abstract Checkpoint blockade results in moderate survival benefit in a subset of patients with triple-negative breast cancer (TNBC) but most patients currently fail to benefit from immunotherapy. We recently discovered that the genes encoding the integrin αV and SOX4 proteins (ITGAV and SOX4 genes) render tumor cells resistant to killing by cytotoxic T cells. Integrin αVβ6 and SOX4 form a resistance pathway that is particularly relevant to TNBC: Integrin αVβ6 releases TGFβ from an inactive latent complex by a force-dependent mechanism, and active TGFβ induces expression of the SOX4 transcription factor that inhibits T cell-mediated tumor immunity. The integrin αVβ6 heterodimer is expressed at a low level by healthy epithelial cells, but its expression is highly upregulated in many epithelial cancers, including TNBC. TGFβ is an important immunosuppressive cytokine in human tumors, but has been difficult to target due to its pleiotropic biology in different cell types and tissues. This approach provides an opportunity for more selective targeting of TGFβ for cancer immunotherapy. Our preliminary data demonstrate that an integrin αVβ6 blocking mAb inhibits SOX4 expression and sensitizes TNBC cells to cytotoxic T cells. This antibody confers a substantial survival benefit in two aggressive mouse models of TNBC that are resistant to checkpoint blockade. In Aim 1, we will study the integrin αVβ6 – SOX4 resistance pathway as an immunotherapy target in aggressive and highly metastatic mouse models of TNBC. In particular, we will examine how inhibition of integrin αVβ6 induces a substantial influx of CD8 T cells into TNBCs that are poorly infiltrated by T cells. In Aim 2, we will investigate the molecular mechanisms by which the integrin αVβ6 – SOX4 pathway inhibits T cell-mediated tumor immunity. Preliminary data demonstrate that the SOX4 transcription factor inhibits expression of genes from multiple innate immune pathways in tumor cells, including the cytosolic dsRNA and dsDNA sensing pathways as well as the type 1 interferon response pathway. We will define the direct transcriptional targets of SOX4 and study how SOX4 cooperates with other transcription factors to render tumor cells resistant to T cell-mediated tumor immunity. In Aim 3, we will study the significance of the integrin αVβ6 – SOX4 pathway in human TNBC. Our hypothesis is that this resistance pathway inhibits T cell infiltration in human TNBC, and we will therefore examine the spatial relationship between integrin αVβ6/SOX4 expression and T cell infiltration in human TNBC specimens. High-affinity integrin αVβ6 antibodies and a small molecule inhibitor are already being tested in clinical trials for fibrosis indications. The studies described here could thus provide the scientific rationale for testing of such inhibitors in TNBC and other human cancers of epithelial origin.
靶向治疗三阴性乳腺癌的主要免疫耐药途径 摘要 检查点阻断可使一部分三阴性乳腺癌患者获得中度生存获益 癌症(TNBC),但大多数患者目前未能受益于免疫疗法。我们最近发现, 编码整合素αV和SOX 4蛋白的基因(ITGAV和SOX 4基因)使肿瘤细胞对 细胞毒性T细胞的杀伤。整合素αVβ6和SOX 4形成了一条与耐药相关的耐药途径, TNBC:整合素αVβ6通过力依赖性机制从无活性的潜伏复合物中释放TGFβ, 活性TGFβ诱导抑制T细胞介导的肿瘤免疫的SOX 4转录因子的表达。 整合素αVβ6异源二聚体在健康上皮细胞中表达水平较低,但其表达水平较低。 在许多上皮癌中高度上调,包括TNBC。TGFβ是一种重要的免疫抑制因子, 细胞因子,但由于其在不同细胞类型中的多效性生物学, 组织中这种方法为更有选择性地靶向TGFβ治疗癌症提供了机会 免疫疗法我们的初步数据表明,整合素αVβ6阻断单克隆抗体抑制SOX 4 表达并使TNBC细胞对细胞毒性T细胞敏感。这种抗体赋予一个实质性的生存效益 在对检查点阻断具有抗性的两种侵袭性TNBC小鼠模型中。在目标1中,我们将研究 整合素αVβ6 -SOX 4抗性通路作为侵袭性和高转移性肿瘤免疫治疗靶点 TNBC小鼠模型。特别是,我们将研究整合素αVβ6的抑制如何诱导实质性的 CD 8 T细胞流入T细胞浸润不良的TNBC。在目标2中,我们将研究 整合素αVβ6 -SOX 4通路抑制T细胞介导的肿瘤免疫的分子机制。 初步数据表明,SOX 4转录因子抑制来自多种细胞的基因表达, 肿瘤细胞中的先天免疫途径,包括胞质dsRNA和dsDNA传感途径以及 作为1型干扰素反应途径。我们将定义SOX 4的直接转录靶点,并研究 SOX 4如何与其他转录因子合作使肿瘤细胞对T细胞介导的肿瘤产生抗性 免疫力在目的3中,我们将研究整合素αVβ6 -SOX 4通路在人TNBC中的意义。我们 假设是这种抗性途径抑制人TNBC中的T细胞浸润,因此我们将 检查人TNBC中整合素αVβ6/SOX 4表达与T细胞浸润之间的空间关系 标本高亲和力整合素αVβ6抗体和一种小分子抑制剂已经在 纤维化适应症的临床试验。因此,这里描述的研究可以为以下方面提供科学依据: 在TNBC和其他上皮来源的人类癌症中测试这种抑制剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kai W Wucherpfennig其他文献

Cracking the code of human T-cell immunity
破解人类 T 细胞免疫的密码
  • DOI:
    10.1038/nbt.2626
  • 发表时间:
    2013-07-09
  • 期刊:
  • 影响因子:
    41.700
  • 作者:
    Christopher J Harvey;Kai W Wucherpfennig
  • 通讯作者:
    Kai W Wucherpfennig
4-1bb Enrichment Enhances Adoptive T Cell Therapy for Hematological Malignancies Using a Novel Approach for Ex Vivo Immune Cell Priming with DC/Tumor Fusion Vaccine
  • DOI:
    10.1182/blood-2023-182381
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Kathrine S Rallis;Jessica Liegel;Giulia Cheloni;Poorva Bindal;Isabella Saldarriaga;Junyan Zhang;Georges Chedid;Joseph Abirached;John G. Clohessy;Sophia Adamia;Kai W Wucherpfennig;Donald Kufe;Jacalyn Rosenblatt;David Avigan
  • 通讯作者:
    David Avigan
Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1
  • DOI:
    10.1182/blood-2024-200876
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Prateek Pophali;Giulia Cheloni;Richard M. Stone;Kai W Wucherpfennig;Aric C. Hall;Amir T. Fathi;Lina Bisharat;Emma K Logan;Yiwen Liu;Donna S. Neuberg;Malgorzata McMasters;Jessica Liegel;Jacqueline S. Garcia;Daniel J. DeAngelo;Michele Narcis;Dina Stroopinsky;Pavania Elavalakanar;Ioannis S Vlachos;Ilene A. Galinsky;Jason Pyrdol
  • 通讯作者:
    Jason Pyrdol
Advances in CD137-Enriched Adoptive T Cell Therapy for Acute Myeloid Leukemia Via Ex Vivo Immune Cell Priming with DC/AML Fusion Vaccine
  • DOI:
    10.1182/blood-2024-208563
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Kathrine S Rallis;Jessica Liegel;Giulia Cheloni;Poorva Bindal;Isabella Saldarriaga;Junyan Zhang;Georges Chedid;Joseph Abirached;Jonah Lee;John G. Clohessy;Samprity Ankita;Rajeev Relangi;Lina Bisharat;Hazal Toros;Sophia Adamia;Jasper B Lee;Donald Kufe;Kai W Wucherpfennig;Jacalyn Rosenblatt;David Avigan
  • 通讯作者:
    David Avigan

Kai W Wucherpfennig的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kai W Wucherpfennig', 18)}}的其他基金

Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
MICA 免疫逃避的治疗靶向 - NKG2D 通路
  • 批准号:
    10380449
  • 财政年份:
    2021
  • 资助金额:
    $ 48.54万
  • 项目类别:
Core 1: Tumor Processing and Single Cell RNA sequencing Core
核心1:肿瘤处理和单细胞RNA测序核心
  • 批准号:
    10210225
  • 财政年份:
    2020
  • 资助金额:
    $ 48.54万
  • 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
  • 批准号:
    10029035
  • 财政年份:
    2020
  • 资助金额:
    $ 48.54万
  • 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
  • 批准号:
    10210221
  • 财政年份:
    2020
  • 资助金额:
    $ 48.54万
  • 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
  • 批准号:
    10400167
  • 财政年份:
    2020
  • 资助金额:
    $ 48.54万
  • 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
  • 批准号:
    10477984
  • 财政年份:
    2020
  • 资助金额:
    $ 48.54万
  • 项目类别:
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
靶向三阴性乳腺癌的主要免疫逃避途径
  • 批准号:
    10668947
  • 财政年份:
    2020
  • 资助金额:
    $ 48.54万
  • 项目类别:
Proj. 3: Immunosuppressive circuits in T cells and other immune cells in GBM patients enrolled in clinical trials
项目。
  • 批准号:
    10684029
  • 财政年份:
    2020
  • 资助金额:
    $ 48.54万
  • 项目类别:
Core 1: Tumor Processing and Single Cell RNA sequencing Core
核心1:肿瘤处理和单细胞RNA测序核心
  • 批准号:
    10684050
  • 财政年份:
    2020
  • 资助金额:
    $ 48.54万
  • 项目类别:
Core 1: Tumor Processing and Single Cell RNA sequencing Core
核心1:肿瘤处理和单细胞RNA测序核心
  • 批准号:
    10477994
  • 财政年份:
    2020
  • 资助金额:
    $ 48.54万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 48.54万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 48.54万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 48.54万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.54万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 48.54万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 48.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 48.54万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 48.54万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 48.54万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 48.54万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了